Company Analysis
Sign in

Mesoblast Limited (MESO)

Nasdaq: MESO · Biological Products, (No Diagnostic Substances) · Melbourne, Victoria, AU · filing with the SEC since 2005
Full chart Alerts Compare
Grade5.5
◀ Past 4.5● Present 5.1▶ Future 6.4
2 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

40 patents granted to the 2 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Mesoblast Limited’s names, not what it holds today.

Patents granted
40
40 utility, 1976 to Dec 31, 2025
Granted in 2025
5
Against 1 in 2024 and 5 in 2023
Applications published
75
10 of them in 2025
Names they are printed under
2
a subsidiary
By yearGrantedApplications published
'14'15'16'17'18'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals13
Biotechnology4
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name2 counted
Mesoblast International Sàrl a subsidiary
CH, as the owner printed on each patent. 1 more under the same name are not counted (printed in AU)
40 granted
32 published
Mesoblast International Sárl a subsidiary
named as the applicant on its applications, in CH
0 granted
43 published
Names not counted (2)
MESOBLAST LTD
Most of its patents print US; this name counts in AU. 30 granted and 47 published under it are not counted.
MESOBLAST LTD
Most of its patents print US; this name counts in AU. 0 granted and 20 published under it are not counted.
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Nov 18, 202512,473,547Use of mesenchymal lineage precursor cells or stem cells (MLPSCs) for delivery of oligonucleotides in the treatment of cancerBiotechnologyMesoblast International Sàrl
Sep 9, 202512,410,405Enhanced MSC preparationsPharmaceuticalsMesoblast International Sàrl
May 20, 202512,303,536Method for treating heart failurePharmaceuticalsMesoblast International Sàrl
Mar 25, 202512,257,270Treatment of immune disordersPharmaceuticalsMesoblast International Sàrl
Feb 4, 202512,215,352Cell culture method for mesenchymal stem cellsBiotechnologyMesoblast International Sàrl
Oct 15, 202412,115,194Prevention of progressive heart failurePharmaceuticalsMesoblast International Sàrl
Nov 21, 202311,821,004Mesenchymal stem cells expressing TNF-α receptorsPharmaceuticalsMesoblast International Sàrl
Oct 24, 202311,795,435Potency assayPharmaceuticalsMesoblast International Sàrl
Aug 1, 202311,712,452Method for treating heart failurePharmaceuticalsMesoblast International Sàrl
Jul 25, 202311,708,560Enhanced MSC preparationsPharmaceuticalsMesoblast International Sàrl
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Oct 16, 20252025/0319428HIGH FLOW FILTER AND METHOD OF USEBiotechnologyMesoblast International Sárl
Oct 16, 20252025/0319134TREATMENT OF IMMUNE DISORDERSPharmaceuticalsMesoblast International Sàrl
Oct 9, 20252025/0312379PURIFIED MESENCHYMAL STEM CELL COMPOSITIONS AND METHODS OF PURIFYING MESENCHYMAL STEM CELL COMPOSITIONSPharmaceuticalsMesoblast International Sárl
Aug 7, 20252025/0249043METHOD FOR TREATING HEART FAILUREPharmaceuticalsMesoblast International Sàrl
May 22, 20252025/0161365METHOD FOR TREATING OR PREVENTING GASTROINTESTINAL BLEEDINGPharmaceuticalsMesoblast International Sárl
May 1, 20252025/0136944STEM CELL COMPOSITIONPharmaceuticalsMesoblast International Sàrl
Apr 24, 20252025/0129337CELL CULTURE METHOD FOR MESENCHYMAL STEM CELLSBiotechnologyMesoblast International Sàrl
Mar 20, 20252025/0090589METHOD OF TREATING PROGRESSIVE HEART FAILURE IN SUBJECTS AT HIGH RISK OF POOR OUTCOMESPharmaceuticalsMesoblast International Sárl
Feb 27, 20252025/0064858PREVENTION OF PROGRESSIVE HEART FAILUREPharmaceuticalsMesoblast International Sàrl
Jan 30, 20252025/0032552METHOD OF TREATING SEVERE GRAFT VERSUS HOST DISEASEPharmaceuticalsMesoblast International Sárl
What it applied for, 2024 to 2025: Pharmaceuticals 15 · Biotechnology 3.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton MESO · research, not advice